Elizabeth Benz

Elizabeth Benz

Auto-generated profile, based on publicly available information

Elizabeth Benz

Human Nutrition Unit Clermont Auvergne University, Institut National de Recherche Pour l'Agriculture, l'Alimentation et l'Environnement, Centre de Recherche en Nutrition Humaine Clermont‐Ferrand France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
EBElizabeth Benz
Elizabeth Benz
SWSara Wijnant
Sara Wijnant
KTKaterina Trajanoska
Katerina Trajanoska
JAJohnmary T. Arinze
Johnmary T. Arinze
EREmmely W. de Roos
Emmely W. de Roos
GBGuy G. Brusselle
Guy G. Brusselle
Background: Increasing evidence suggests that sarcopenia and a higher systemic immune-inflammation index (SII) are linked with morbidity in patients with COPD. However, whether these two conditions contribute to all-cause mortality in middle-aged and older patients with COPD or asthma is unclear. Therefore, we investigated the association between sarcopenia, SII, COPD or asthma and all-cause mortality in a large-scale population-based setting.Methods: Between 2009 and 2014, 4482 participants (aged >55 years; 57.3% female) from the population-based Rotterdam Study were included. COPD and asthma patients were diagnosed clinically and based on spirometry. Six study groups were defined according to the presence or absence of COPD or asthma and sarcopenia. Cox regression models were used to assess all-cause mortality in the study groups, adjusted for sex, age, body mass index, SII, smoking, oral corticosteroid use and comorbidities. In addition, all participants were categorised into sex-specific quartiles of SII, and mortality in these groups was compared.Results: Over a median follow-up of 6.1 years (interquartile range 5.0–7.2 years), 466 (10.4%) persons died. Independent of the presence of sarcopenia, participants with COPD had a higher risk of all-cause mortality (hazard ratio (HR) 2.13, 95% CI 1.46–3.12 and HR 1.70, 95% CI 1.32–2.18 for those with and without sarcopenia, respectively). Compared to lower SII levels, higher SII levels increased mortality risk even in people without sarcopenia, COPD or asthma.Conclusion: Middle-aged and older people with COPD, higher SII levels or sarcopenia had an independently increased mortality risk. Our study suggests prognostic usefulness of routinely evaluating sarcopenia and SII in older people with COPD or asthma.

27 July 2023 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
EBElizabeth Benz
Elizabeth Benz
LLLies Lahousse
Lies Lahousse
JAJohnmary T. Arinze
Johnmary T. Arinze
SWSara Wijnant
Sara Wijnant
MRMaria de Ridder
Maria de Ridder
BSBruno H. Stricker
Bruno H. Stricker
Background: Sarcopenia is characterised by two major phenotypic components: low handgrip strength (HGS) and appendicular skeletal muscle index (ASMI). Oral corticosteroid (OCS) use is an important medication for acute respiratory exacerbations in patients with COPD and asthma. However, the association of OCS and sarcopenia components in older people is largely unexplored. The aim of this study was to examine the association between OCS use and HGS or ASMI in the general population and explore interactions with chronic airway diseases. Methods: From the population-based Rotterdam Study, 5054 participants (age 69.0±8.8 years; 56% females) were included in the cross-sectional analysis and 1324 in the longitudinal analysis. Associations between OCS and muscle strength and mass were analysed using linear regression models adjusted for age, sex, fat %, height, kidney function, smoking and comorbidities. Results: At baseline, ever-OCS users had lower handgrip strength (β= −0.48, 95% CI −0.84– −0.12) than never-OCS users, with cumulative frequency (≥10 OCS prescriptions)-dependent effects (β= −1.25, 95% CI −2.16– −0.33). COPD ever-OCS users, but not asthma, had lower handgrip strength (β= −0.98, 95% CI −1.91– −0.06) and lower lean mass (β= −0.14, 95% CI −0.27– −0.01) than never-OCS users. After 5.6 years of follow-up in those free of sarcopenia traits at baseline, COPD ever-OCS users developed lower handgrip strength (β= −1.64, 95% CI −2.87– −0.40) with frequency (β= −3.64, 95% CI −6.57– −0.72) and duration (β= −1.51, 95% CI −2.87– −0.15) association compared to never-OCS users. Conclusions: OCS use is associated with a decline in handgrip strength in people with COPD in a cumulative frequency and duration-dependent manner. Routine muscle examination may be necessary for patients with COPD.

15 October 2025 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
EBElizabeth Benz
Elizabeth Benz
APAlexandre Pinel
Alexandre Pinel
CGChristelle Guillet
Christelle Guillet
FCFrederic Capel
Frederic Capel
BPBruno Pereira
Bruno Pereira
YBYves Boirie
Yves Boirie
Background: Sarcopenic obesity (SO) is a clinical condition defined by the coexistence of high body fat mass and low muscle function and mass, which increases the risk of adverse health outcomes, including disability and mortality. Early detection and frequent monitoring of SO are essential for preventive interventions and management strategies. The current binary approach for SO diagnosis is limited in capturing the spectrum of SO or its progression over time. The main objective of this study was to develop a continuous SOP i that integrates diagnostic criteria such as muscle function and body composition. We aimed to evaluate the association between SOP i and all‐cause mortality, to identify baseline‐related factors with SOP i and to assess changes in the SOP i over time. Methods: Participants from the Rotterdam Study with baseline and follow‐up measures of handgrip strength (HGS), dual‐energy X‐ray absorptiometry‐measured appendicular lean mass index (ALM/kg) and body fat percentage (BF%) were included. SOP i was calculated as a sex‐specific equation integrating z‐scores (Z) of (BF%)—(HGS)—(ALM/kg). Cox regression and multivariable linear regression models were fitted to evaluate mortality risk and associated factors with SOP i , respectively. Subgroup analysis of SOP i changes was performed by linear mixed‐effects models. Results: In the total population ( n = 5888, age 69.5 ± 9.1 years, BMI 27.5 ± 4.3 kg/m 2 , 56.8% females) and over the 9.9‐year median follow‐up period, 1538 (26.1%) participants died. Each standard deviation (SD) increase in sex‐specific SOP i was associated with a 10% higher risk of premature death (HR = 1.10 [95%CI: 1.07; 1.13]). Thirteen factors were associated with high SOP i , such as reduced physical activity, higher triglyceride‐glucose index, HOMA‐IR, systemic inflammation, osteopenia, hypertension, liver steatosis, asthma, coronary heart disease, oral corticosteroid use, lower protein intake, lower quality of life and lower educational status. In participants with obesity, lower physical activity and/or insulin resistance ( n = 1682), a significantly higher and faster increase in SOP i was observed compared to participants without these factors (males: β = 2.63 [95%CI: 2.22; 3.03]; females: β = 2.90 [95%CI: 2.58; 3.23]). Conclusion: SOP i is a significant predictor of premature death and can identify associated factors, particularly useful among persons at risk of SO. SOP i is higher and increases faster in individuals with specific phenotypes. SOP i integrates prognosis information, which could be used as a risk indicator and for prevention of SO.

15 June 2022 in Bone Reports
Verified
Journal Article
Open access
EBElizabeth Benz
Elizabeth Benz
CGCarolina Medina Gomez
Carolina Medina Gomez
JAJohnmarie Arinze
Johnmarie Arinze
JLJiawei Li
Jiawei Li
KTKaterina Trajanoska
Katerina Trajanoska
RFRivadeneira Fernando
Rivadeneira Fernando